LB Pharmaceuticals, Inc. (LBRX)
48.31
-0.49
(-1.00%)
USD |
NASDAQ |
Aug 26, 11:24
LB Pharmaceuticals Total Liabilities (Quarterly) : 29.34M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 29.34M |
| March 31, 2026 | 14.79M |
| December 31, 2025 | 11.62M |
| September 30, 2025 | 10.52M |
| June 30, 2025 |
| Date | Value |
|---|---|
| March 31, 2025 | |
| December 31, 2024 | 13.83M |
| September 30, 2024 | |
| June 30, 2024 | |
| March 31, 2024 | 10.45M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Ligand Pharmaceuticals, Inc. | 1.218B |
| Neumora Therapeutics, Inc. | 80.73M |
| ANI Pharmaceuticals, Inc. | 896.90M |
| Corcept Therapeutics, Inc. | 182.93M |
| Veru, Inc. | 8.651M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 361.69M |
| Shareholders Equity (Quarterly) | 332.35M |
| Debt to Equity Ratio | 0.0157 |
| Current Ratio | 15.08 |
| Net Debt Paydown Yield | -0.11% |